Half Year 2024 Integral Diagnostics Ltd Earnings Call Transcript
Key Points
- Integral Diagnostics Ltd (ASX:IDX) achieved solid organic revenue growth of 7.2% in the first half of FY '24.
- Operating EBITDA increased by 8.7% to $43.2 million, with a slightly higher EBITDA margin of 18.7%.
- The company served 600,000 patients and performed over 1.3 million exams in the first half.
- IDX declared a fully franked interim dividend of $0.025 per share.
- The teleradiology business, IDXt, continues to grow, now accounting for about 15% of revenues and offering higher margins.
- Operating net profit after tax declined by 5.6% to $7.4 million due to prolonged cost inflation and higher interest rates.
- Statutory NPAT declined by $66.8 million, driven by a non-cash impairment of the New Zealand business.
- Free cash flow decreased by 41.3% due to timing of working capital movements.
- Net debt-to-EBITDA ratio remains high at 3.0x, although slightly improved from 3.1x the previous year.
- The company faces ongoing labor cost pressures, particularly in regional areas, driven by inflation and labor market supply constraints.
Thank you for standing by, and welcome to the Integral Diagnostics Fiscal Year '24 IDX Half Year Results Call. (Operator Instructions)
I would now like to hand the conference over to Dr. Ian Kadish, CEO. Please go ahead.
Thank you very much. My name is Ian Kadish. I'm the Chief Executive Officer and Managing Director of Integral Diagnostics. I'm joined here this morning by Craig White, the Chief Financial Officer of Integral Diagnostics. And we're pleased this morning to be able to share IDX's first half financial year '24 financial results with you.
At IDX, our vision is to build a healthier world and we do this by delivering the best health outcome for every patient we serve. We always put our patients first, we demonstrate medical leadership. We ensure that everyone counts. We create value and we embrace change.
We delivered on our values in the first half of '24 by serving 600,000 patients in the first half. We performed more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
